Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 50, 2014, Pages 17965-17970

  Kabanova, Anna ^a   Perez, Laurent ^a   Lilleri, Daniele ^a,b   Marcandalli, Jessica ^a   Agatic, Gloria ^c   Becattini, Simone ^a   Preite, Silvia ^a   Fuschillo, Dario ^a   Percivalle, Elena ^b   Sallusto, Federica ^a   Gerna, Giuseppe ^b   Corti, Davide ^c   Lanzavecchia, Antonio ^a,d  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Humabs BioMed SA ^*  (Switzerland)

^d ETH ZURICH   (Switzerland)

Author keywords

Analytic vaccinology; Human cytomegalovirus; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GHGLPUL128L PENTAMER; GLYCOPROTEIN B; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; CELL SPREADING; CHO CELL LINE; COMPLEX FORMATION; CYTOMEGALOVIRUS INFECTION; DRUG FORMULATION; DRUG POTENCY; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LEUKOCYTE; MEMORY CELL; MOUSE; NONHUMAN; STABLE TRANSFECTION; VACCINATION; ANIMAL; CRICETULUS; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; HAMSTER; HEK293 CELL LINE; IMMUNOLOGY; ISOLATION AND PURIFICATION; NONPARAMETRIC TEST;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; CHO CELLS; CRICETINAE; CRICETULUS; CYTOMEGALOVIRUS VACCINES; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; STATISTICS, NONPARAMETRIC; VACCINES, SUBUNIT;

EID: 84918495021     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1415310111     Document Type: Article

References (42)

1. Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17(4):253-276.
2. Streblow DN, Orloff SL, Nelson JA (2007) Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 19(5):577-582.
3. Moss P (2010) The emerging role of cytomegalovirus in driving immune senescence: A novel therapeutic opportunity for improving health in the elderly. Curr Opin Immunol 22(4):529-534.
4. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA (2008) Mechanisms of cytomegalovirus-accelerated vascular disease: Induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 325:397-415.
5. Compton T (2004) Receptors and immune sensors: The complex entry path of human cytomegalovirus. Trends Cell Biol 14(1):5-8.
6. Ryckman BJ, et al. (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82(1):60-70.
7. Dargan DJ, et al. (2010) Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 91(Pt 6):1535-1546.
8. Gerna G, et al. (2005) Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 86(Pt 2):275-284.
9. Hahn G, et al. (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78(18):10023-10033.
10. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102(50):18153-18158.
11. Vanarsdall AL, Chase MC, Johnson DC (2011) Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol 85(22):11638-11645.
12. Krause PR, et al. (2013) Priorities for CMV vaccine development. Vaccine 32(1):4-10.
13. Griffiths P, et al. (2013) Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31(Suppl 2):B197-B203.
14. Plotkin SA, et al. (1984) Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1(8376):528-530.
15. Lilja AE, Mason PW (2012) The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30(49):6980-6990.
16. Pass RF (2009) Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 46(Suppl 4):S73-S76.
17. Griffiths PD, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 377(9773):1256-1263.
18. Pötzsch S, et al. (2011) B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7(8):e1002172.
19. Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26(45):5760-5766.
20. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee (2004) Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis 39(2):233-239.
21. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353(13):1350-1362.
22. Revello MG, et al.; CHIP Study Group (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370(14):1316-1326.
23. Macagno A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84(2):1005-1013.
24. Lilleri D, et al. (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS ONE 8(3):e59863.
25. Traggiai E, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10(8):871-875.
26. Lai RPJ, et al. (2012) Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS ONE 7(4):e35083.
27. Szymczak AL, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22(5):589-594.
28. Garc¸on N, Van Mechelen M (2011) Recent clinical experience with vaccines using MPLand QS-21-containing adjuvant systems. Expert Rev Vaccines 10(4):471-486.
29. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32(6):1324-1331.
30. Lanzavecchia A, et al. (2006) Understanding and making use of human memory B cells. Immunol Rev 211:303-309.
31. Freed DC, et al. (2013) Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci USA 110(51):E4997-E5005.
32. Wussow F, et al. (2013) A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87(3):1322-1332.
33. Wen Y, et al. (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32(30):3796-3804.
34. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104.
35. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705-742.
36. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC (2010) A human cytomegalovirus gO-nullmutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84(5):2585-2596.
37. Heldwein EE, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313(5784):217-220.
38. Corti D, et al. (2013) Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501(7467):439-443.
39. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592-598.
40. Eisenberg RJ, et al. (2012) Herpes virus fusion and entry: A story with many characters. Viruses 4(5):800-832.
41. Carlson C, Britt WJ, Compton T (1997) Expression, purification, and characterization of a soluble form of human cytomegalovirus glycoprotein B. Virology 239(1):198-205.
42. Gerna G, et al. (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89(Pt 4):853-865.